BVXV - BiondVax soars 35% amid former CFO of GSK's global vaccines business joining board
BiondVax Pharmaceuticals (NASDAQ:BVXV) appointed former CFO of GlaxoSmithKline's (NYSE:GSK) global vaccines business Jay Green to its board of directors. Green recently completed a six-year term as Senior Vice President Finance and CFO of GlaxoSmithKline's global vaccines business. The company added that Isaac Devash retired from the board. BiondVax said all proposed resolutions were approved at its annual general meeting. BiondVax's Chairman Mark Germain said "We're very excited to have Jay join our board of directors, particularly as we relaunch the company's R&D efforts around the unique nanosized antibody (NanoAb) program in collaboration with the Max Planck Institute. Jay's experience serving as GSK Vaccine's SVP Finance/CFO and his current involvement in the global COVID–19 response as an advisor to Gavi for COVAX is highly relevant and adds a significant dimension to our Board." BVXV +35.62% to $3.16 pre-market
For further details see:
BiondVax soars 35% amid former CFO of GSK's global vaccines business joining board